- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Endometrial cancer
- Meeting Date: May 2025
- Public Summary Document (PSD) May 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) May 2025 PBAC Meeting - (Word)
Dostarlimab – May 2025
Dostarlimab: Solution concentrate for I.V. infusion 500 mg in 10 mL; Jemperli®
Last updated
9 May 2025